Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Health-Related Quality of Life During Routine Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-Interventional Observational Study.

Horn A, Zeuner H, Wolf H, Schnitker J, Wüstenberg E; GRAZAX LQ-study group.

Clin Drug Investig. 2016 Jun;36(6):453-62. doi: 10.1007/s40261-016-0388-9.

2.

Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study.

Reiber R, Keller M, Keller W, Wolf H, Schnitker J, Wüstenberg E.

Clin Transl Allergy. 2016 Mar 8;6:9. doi: 10.1186/s13601-016-0097-8. eCollection 2015.

3.

Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes.

Steveling EH, Lao-Araya M, Koulias C, Scadding G, Eifan A, James LK, Dumitru A, Penagos M, Calderón M, Andersen PS, Shamji M, Durham SR.

Clin Transl Allergy. 2015 Dec 17;5:43. doi: 10.1186/s13601-015-0087-2. eCollection 2015.

4.

Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis.

Scaparrotta A, Attanasi M, Petrosino MI, Di Filippo P, Di Pillo S, Chiarelli F.

Drug Des Devel Ther. 2015 Nov 3;9:5897-909. doi: 10.2147/DDDT.S70432. eCollection 2015. Review.

5.

Is clinical tolerance possible after allergen immunotherapy?

Moran TP, Burks AW.

Curr Allergy Asthma Rep. 2015 May;15(5):23. doi: 10.1007/s11882-015-0523-3. Review.

7.

Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol.

Makatsori M, Senna G, Pitsios C, Lleonart R, Klimek L, Nunes C, Rukhadze M, Rogala B, Gawlik R, Panzner P, Pfaar O, Calderon M.

Clin Transl Allergy. 2015 Apr 27;5:17. doi: 10.1186/s13601-015-0060-0. eCollection 2015.

8.

Immunology of IgG4-related disease.

Della-Torre E, Lanzillotta M, Doglioni C.

Clin Exp Immunol. 2015 Aug;181(2):191-206. doi: 10.1111/cei.12641. Epub 2015 Jun 8. Review.

PMID:
25865251
9.

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany.

Verheggen BG, Westerhout KY, Schreder CH, Augustin M.

Clin Transl Allergy. 2015 Jan 21;5:1. doi: 10.1186/s13601-015-0045-z. eCollection 2015.

10.

Role of immunotherapy in the treatment of allergic asthma.

Yukselen A, Kendirli SG.

World J Clin Cases. 2014 Dec 16;2(12):859-65. doi: 10.12998/wjcc.v2.i12.859. Review.

11.

New treatments for allergen immunotherapy.

Akdis M.

World Allergy Organ J. 2014 Sep 24;7(1):23. doi: 10.1186/1939-4551-7-23. eCollection 2014. Review.

12.

Oral and sublingual immunotherapy.

Kim EH, Burks W.

Curr Treat Options Allergy. 2014 Mar 1;1(1):48-57.

13.

Trends in Specific Immunotherapy for Allergic Rhinitis: A Survey of Chinese ENT Specialists.

Zhou H, Tao QL, Wei JM, Xu G, Cheng L.

Allergy Asthma Immunol Res. 2014 Jul;6(4):296-303. doi: 10.4168/aair.2014.6.4.296. Epub 2014 Feb 13.

14.

Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy.

Poole CD, Bannister CA, Andreasen JN, Andersen JS, Currie CJ.

Health Qual Life Outcomes. 2014 Jun 13;12:99. doi: 10.1186/1477-7525-12-99.

15.

A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.

Devillier P, Dreyfus JF, Demoly P, Calderón MA.

BMC Med. 2014 May 1;12:71. doi: 10.1186/1741-7015-12-71. Review.

16.

Decision-making analysis for allergen immunotherapy versus nasal steroids in the treatment of nasal steroid-responsive allergic rhinitis.

Kennedy JL, Robinson D, Christophel J, Borish L, Payne S.

Am J Rhinol Allergy. 2014 Jan-Feb;28(1):59-64. doi: 10.2500/ajra.2014.28.3998.

17.

Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, Bousquet J, Calderón M, Compalati E, Durham SR, van Wijk RG, Larenas-Linnemann D, Nelson H, Passalacqua G, Pfaar O, Rosário N, Ryan D, Rosenwasser L, Schmid-Grendelmeier P, Senna G, Valovirta E, Van Bever H, Vichyanond P, Wahn U, Yusuf O.

World Allergy Organ J. 2014 Mar 28;7(1):6. doi: 10.1186/1939-4551-7-6.

18.

Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure.

Durham SR, Nelson HS, Nolte H, Bernstein DI, Creticos PS, Li Z, Andersen JS.

Allergy. 2014 May;69(5):617-23. doi: 10.1111/all.12373. Epub 2014 Mar 10.

19.

Implementing specific oral tolerance induction to milk into routine clinical practice: experience from first 50 patients.

Luyt D, Bravin K, Luyt J.

J Asthma Allergy. 2014 Jan 28;7:1-9. doi: 10.2147/JAA.S53281. eCollection 2014.

20.

Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE).

Slovick A, Douiri A, Kelly J, Guerra A, Muir R, Tsioulos K, Murphy C, Shamji MH, Ying S, Durham SR, Till SJ.

Clin Transl Allergy. 2013 Aug 21;3(1):27. doi: 10.1186/2045-7022-3-27.

Items per page

Supplemental Content

Write to the Help Desk